UNSPSC 51151501: Bethanechol

This classification denotes an antimuscarinic agent with the molecular formula C7H17N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 004F72P8F4, chemically known as 2-((aminocarbonyl)oxy)-n,n,n-trimethyl-1-propanaminium but generally known as bethanechol, which bears US NIH Compound Identifier 2370. European Medicines Agency schedules Bethanechol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13063MIG.

World Health Organization schedules bethanechol in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, BETHANECHOL remains the US FDA Preferred Term for this commodity. Bethanechol bears US NLM identifiers UMLS ID C0053526 and NCI Concept Code C76039. SMILES: O(C(C[N](C)(C)C)C)C(=O)N.

UNSPSC 51151501 Bethanechol is a Commodity code that in recent state and local procurement activity covers the purchase of pharmaceutical products and related health-delivery systems, though the recent opportunities show minimal direct alignment with the code's nominal scope. Seminole County, Florida's IFB60459723LAS sought 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building and a two-year initial term with a one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 to gather market intelligence on implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, soliciting vendor capabilities for direct contracting with self-insured employers and state agencies outside traditional pharmacy benefit manager, group purchasing organization, and wholesaler channels. Issuing bodies under this code include county health departments and state health commissions pursuing pharmaceutical procurement and related health-delivery infrastructure.

Recent activity concentrates in Florida and Texas. Seminole County's Naloxone and drug deactivation procurement (IFB, due July 26, 2023) required vendors to submit electronic bids with unit pricing, comply with drug-free workplace and E-Verify requirements, and maintain workers' compensation, commercial general liability, and professional liability insurance; the contract was potentially FEMA-funded and carried a three-month probationary period. The Texas HHS RFI (posted April 3, 2026, response deadline April 3, 2026) functioned as exploratory market research rather than a binding solicitation, seeking vendor experience with direct contracting, negotiated net pricing models without rebates, and value-based or outcomes-based agreements to inform future formal procurement strategy. The code shows sparse recent activity and the opportunities listed carry substantial misalignment with bethanechol specifically, suggesting limited current procurement velocity under this Commodity designation.